Atogepant for preventive treatment of episodic cluster headache: A single-center case series of 18 patients
Cephalalgia · 2026-11 · 46 (11)
DOI: 10.1177/03331024261495542 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cephalalgia, online erschienen am 03.11.2026. Verfasst von Yooha Hong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea. Hauptthemen laut MEDLINE: Cluster Headache. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Cluster headache (CH) is a highly disabling primary headache disorder characterized by severe unilateral attacks occurring in bouts. Calcitonin gene-related peptide plays a key role in CH pathophysiology, yet preventive treatment options remain limited. We aimed to evaluate the short-term clinical effects of atogepant in patients with episodic CH during an active cluster bout.
Methods
We conducted a single-center real-world observational study. The study protocol included both retrospective and prospective cohorts, but all patients in the present analysis were from the retrospective cohort. Adult patients with episodic CH treated with atogepant during an active bout were consecutively included. Weekly headache outcomes during baseline (the week prior to treatment) and week 1 after atogepant initiation were compared. The primary outcome was change in weekly headache days; secondary outcomes included attack frequency, pain intensity, attack duration, and acute medication use. Responder rates (≥ 50% reduction) and Patient Global Impression of Change (PGIC) were assessed.
Results
Eighteen patients were included (mean age 39.9 ± 11.2 years; 72.2% male). Significant improvements were observed across all outcomes within one week after atogepant initiation. Weekly headache days decreased from 7.0 (5.0–7.0) to 3.0 (2.0–7.0) ( p = 0.008), and attack frequency from 7.5 (5.5–14.0) to 3.0 (2.0–7.0) ( p = 0.018). Pain intensity, attack duration, and acute medication use were also reduced. Large effect sizes were observed (r = 0.56–0.79). A ≥ 50% reduction in headache days occurred in 50.0% of patients and in attack frequency in 81.2%. PGIC ratings indicated that 66.7% of patients were rated as much or very much improved.
Discussion
In this open-label, uncontrolled study, atogepant initiation was associated with short-term improvements across multiple headache outcomes within one week in patients with episodic CH. Given the small sample size, retrospective data collection, short follow-up, and concurrent preventive therapies, these preliminary findings require confirmation in randomized, placebo-controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea.
ORCID-Profile: Yooha Hong, Mi-Kyoung Kang, Soo-Jin Cho
Zitieren
APA
Hong, Y., Kang, M. K., & Cho, S. J. (2026). Atogepant for preventive treatment of episodic cluster headache: A single-center case series of 18 patients. Cephalalgia, 46(11). https://doi.org/10.1177/03331024261495542
Vancouver
Hong Y, Kang MK, Cho SJ. Atogepant for preventive treatment of episodic cluster headache: A single-center case series of 18 patients. Cephalalgia. 2026;46(11). doi:10.1177/03331024261495542
BibTeX
@article{Hong2026,
author = {Hong, Yooha and Kang, Mi-Kyoung and Cho, Soo-Jin},
title = {Atogepant for preventive treatment of episodic cluster headache: A single-center case series of 18 patients},
journal = {Cephalalgia},
year = {2026},
volume = {46},
number = {11},
doi = {10.1177/03331024261495542}
}
EUVIMED